CN113509535A - Cape jasmine-honeysuckle flower-all-grass-all particle formula - Google Patents
Cape jasmine-honeysuckle flower-all-grass-all particle formula Download PDFInfo
- Publication number
- CN113509535A CN113509535A CN202110475408.4A CN202110475408A CN113509535A CN 113509535 A CN113509535 A CN 113509535A CN 202110475408 A CN202110475408 A CN 202110475408A CN 113509535 A CN113509535 A CN 113509535A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- early
- cape jasmine
- selfheal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a gardenia early granule formula, which comprises the following raw material medicaments: 3-9g of radix bupleuri, 7-13g of cape jasmine, 7-13g of scutellaria baicalensis, 3-9g of moutan bark, 7-13g of radix curcumae, 7-13g of rhizoma cyperi, 7-13g of snakegourd fruit, 7-13g of selfheal, 7-13g of thunberg fritillary bulb, 7-13g of lychee seed, 7-13g of bighead atractylodes rhizome, 3-9g of dried orange peel, 3-9g of rhizoma pinelliae preparata and 7-13g of white paeony root. The invention can treat idiopathic central precocious puberty, delay the premature development of secondary sexual characteristics and avoid the early maturation of bones and sexual organs, thereby achieving the treatment purposes of delaying the closing time of epiphyses and the ovarian ovulation time and improving the expected height and the fertility function of children patients.
Description
Technical Field
The invention relates to the field of medicine formulas, in particular to a gardenia early granule formula.
Background
Precocious puberty refers to the development of secondary sexual lesions in girls before the age of 8 and in boys before the age of 9. In recent years, along with the improvement of physical life and nutritional conditions, the chemical pollution is aggravated, the clinical incidence rate of precocious puberty is increased year by year, and the medicine is a frequently encountered disease and a common disease in the endocrinology department of children. Idiopathic central precocious puberty is a common type of precocious puberty, the incidence rate exceeds 92% of all precocious children, the premature initiation is mainly carried out in the hypothalamus-pituitary-gonad axis, the pulse secretion of gonadotropin-releasing hormone is enhanced, the synthesis and release of follicle-stimulating hormone and luteinizing hormone are stimulated, FSH and LH stimulate sex gland to synthesize sex hormones, the puberty and sexual development are advanced, the growth is accelerated, the secondary sexual characteristics are advanced, the uterus ovary is obviously enlarged, the bone age is advanced, and finally the adult height is low.
Gonadotropin releasing hormone analogue is an effective medicine for treating central premature children for nearly 40 years, can effectively inhibit hypothalamus-pituitary-gonad axis, improve growth result, increase height of children patients and achieve the purpose of expected treatment. Triptorelin acetate for injection is used as a representative medicine of GnRHA, the growth axis can be generally inhibited after 4 months of use, but the triptorelin acetate has long administration time and high price, and has various adverse reactions such as abnormal sleep, mood change, headache, hypersensitivity, acne, hyperhidrosis, abnormal mammary gland, genital hemorrhage, ovarian hyperstimulation syndrome, general weakness, fever and the like in the treatment process or in addition, and partial children need to obtain recombinant human growth hormone additionally, so that the triptorelin acetate inevitably brings heavy economic and psychological burdens to the children and families.
In the syndrome differentiation and treatment of the treatment of precocious puberty in the traditional Chinese medicine, the yin deficiency and fire excess type precocious puberty is mainly used in southern areas, and the treatment medicine is the Zhibai Dihuang pill. The cold and cold dry climate and the diet structure mainly with the rich taste in the northern area of China, particularly in the northeast area, lead most children patients to form a special cold region syndrome, namely the liver-phlegm-fire syndrome. The incidence rate of the syndrome accounts for more than 35% of the northern precocious children, and is one of the clinical common syndrome types of the northern precocious children patients. However, for the treatment of the syndrome type, modern medical doctors often cannot accurately distinguish the syndrome, and the treatment effect is the opposite if the pills of Zhibai Dihuang are still used for treatment.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a gardenia early granule formula.
In order to solve the technical problems, the invention provides the following technical scheme:
the invention relates to a gardenia early granule formula, which comprises the following raw material medicaments: 3-9g of radix bupleuri, 7-13g of cape jasmine, 7-13g of scutellaria baicalensis, 3-9g of moutan bark, 7-13g of radix curcumae, 7-13g of rhizoma cyperi, 7-13g of snakegourd fruit, 7-13g of selfheal, 7-13g of thunberg fritillary bulb, 7-13g of lychee seed, 7-13g of bighead atractylodes rhizome, 3-9g of dried orange peel, 3-9g of rhizoma pinelliae preparata and 7-13g of white paeony root.
As a preferred technical scheme of the invention, the formula crude drug is as follows: 6g of radix bupleuri, 10g of cape jasmine, 10g of radix scutellariae, 6g of moutan bark, 10g of radix curcumae, 10g of rhizoma cyperi, 10g of trichosanthes kirilowii maxim, 10g of selfheal, 10g of thunberg fritillary bulb, 10g of lychee seed, 10g of bighead atractylodes rhizome, 6g of dried orange peel, 6g of rhizoma pinelliae preparata and 10g of white paeony root.
As a preferred technical scheme of the invention, the formula crude drug is as follows: 3g of radix bupleuri, 7g of cape jasmine, 7g of radix scutellariae, 3g of moutan bark, 7g of radix curcumae, 7g of rhizoma cyperi, 7g of fructus trichosanthis, 7g of selfheal, 7g of thunberg fritillary bulb, 7g of lychee seed, 7g of rhizoma atractylodis macrocephalae, 3g of dried orange peel, 3g of rhizoma pinelliae preparata and 7g of radix paeoniae alba.
As a preferred technical scheme of the invention, the formula crude drug is as follows: 9g of radix bupleuri, 13g of cape jasmine, 13g of radix scutellariae, 9g of moutan bark, 13g of radix curcumae, 13g of rhizoma cyperi, 13g of trichosanthes kirilowii maxim, 13g of selfheal, 13g of thunberg fritillary bulb, 13g of lychee seed, 13g of rhizoma atractylodis macrocephalae, 9g of dried orange peel, 9g of rhizoma pinelliae preparata and 13g of radix paeoniae alba.
Compared with the prior art, the invention has the following beneficial effects:
the invention can treat idiopathic central precocious puberty, delay the premature development of secondary sexual characteristics and avoid the early maturation of bones and sexual organs, thereby achieving the treatment purposes of delaying the closing time of epiphyses and the ovarian ovulation time and improving the expected height and the fertility function of children patients.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1 is a composition diagram of the formulation of the present invention;
the preferred embodiments of the present invention will be described in conjunction with the accompanying drawings, and it will be understood that they are described herein for the purpose of illustration and explanation and not limitation.
Example 1
As shown in fig. 1, the invention provides a gardenia early granule formula, which comprises the following raw material medicaments: 6g of radix bupleuri, 10g of cape jasmine, 10g of radix scutellariae, 6g of moutan bark, 10g of radix curcumae, 10g of rhizoma cyperi, 10g of trichosanthes kirilowii maxim, 10g of selfheal, 10g of thunberg fritillary bulb, 10g of lychee seed, 10g of bighead atractylodes rhizome, 6g of dried orange peel, 6g of rhizoma pinelliae preparata and 10g of white paeony root.
Example 2
As shown in fig. 1, the invention provides a gardenia early granule formula, which comprises the following raw material medicaments: 3g of radix bupleuri, 7g of cape jasmine, 7g of radix scutellariae, 3g of moutan bark, 7g of radix curcumae, 7g of rhizoma cyperi, 7g of fructus trichosanthis, 7g of selfheal, 7g of thunberg fritillary bulb, 7g of lychee seed, 7g of rhizoma atractylodis macrocephalae, 3g of dried orange peel, 3g of rhizoma pinelliae preparata and 7g of radix paeoniae alba.
Example 3
As shown in fig. 1, the invention provides a gardenia early granule formula, which comprises the following raw material medicaments: 9g of radix bupleuri, 13g of cape jasmine, 13g of radix scutellariae, 9g of moutan bark, 13g of radix curcumae, 13g of rhizoma cyperi, 13g of trichosanthes kirilowii maxim, 13g of selfheal, 13g of thunberg fritillary bulb, 13g of lychee seed, 13g of rhizoma atractylodis macrocephalae, 9g of dried orange peel, 9g of rhizoma pinelliae preparata and 13g of radix paeoniae alba.
Specifically, radix bupleuri relieves stagnation of the liver-qi, and fructus Gardeniae clears away liver fire, so that liver qi can be stripped and latent fire can be cleared, which are monarch drugs together. Baikal skullcap root, bitter and cold in flavor, clears heat and purges fire; cortex moutan has effects in cooling blood and promoting blood circulation; yujin enters liver, gallbladder and heart channels, regulates qi and activates blood circulation, soothes liver and relieves depression; the compatibility of the essence is smooth, so that the essence can pass through the qi system, disperse and resolve six kinds of depression, enter the blood system and dredge the veins; the medicines are used together to dredge the liver and assist the liver, clear and reduce liver fire, harmonize qi and blood and are used as ministerial medicines. The snakegourd fruit clears heat and reduces phlegm, and relieves chest stuffiness and stagnation; softening hard masses, resolving hard masses and eliminating swelling of selfheal, thunberg fritillary bulb and lychee seed; the largehead atractylodes rhizome has the effects of tonifying spleen, regulating qi and reducing phlegm; the dried orange peel and the rhizoma pinelliae preparata are combined for strengthening spleen, eliminating dampness and phlegm, regulating qi and harmonizing middle energizer, and are used as adjuvant drugs together. Bai Shao has the actions of nourishing liver, astringing yin, relieving spasm and pain, tonifying liver, and assisting liver, so as to prevent various pharmacologic actions such as dispersing pathogen accumulation too much and consuming yin and blood, so it is a guiding drug. The medicines are combined to play the roles of dispersing liver qi, lowering fire, reducing phlegm, resolving stagnation, softening and resolving hard mass, so that liver qi stagnation is relaxed, qi movement is good, the opening and closing of the liver and the kidney are orderly, Chong and ren meridians are nodal, and the normal physiological development state is returned.
Case (2): the cold, cold and dry climate and the diet structure mainly with the tastes of fat, sweet and thick in the northern area lead most children patients to form the special cold-region syndrome, namely the liver-stagnated phlegm-fire syndrome. The incidence rate of the syndrome accounts for more than 35% of the northern precocious children, and is one of the common clinical syndromes. The main clinical manifestations are summarized as follows: breast and breast nucleus development, breast distending pain, or distending pain of two ribs, facial acne, or internal and external genitalia development, or appearance of pubic hair and axillary hair, and pigmentation of labia of girls, or yellow and white leucorrhea, even leading menstruation; a boy has a low voice, an enlarged testis and a thickened penis, or has an erection and spermatorrhea. With the symptoms of obesity, vexation, irritability, bitter taste, dry stool, red tongue with yellow and greasy coating, and wiry, slippery or wiry and rapid pulse.
The traditional Chinese medicine Zhizao granules can effectively eliminate or not progress the character of the liver-depression phlegm-fire type precocious children which develops in advance: most children patients take the medicine for about 2 weeks, the breast nuclei become soft or disappear, and the breast distending pain is relieved; the change of the significant retraction of the uterus and the ovary appears around 2 months, and simultaneously, the levels of serum IGF-1, FSH, LH and E2 are significantly reduced
The invention can treat idiopathic central precocious puberty, delay the premature development of secondary sexual characteristics and avoid the early maturation of bones and sexual organs, thereby achieving the treatment purposes of delaying the closing time of epiphyses and the ovarian ovulation time and improving the expected height and the fertility function of children patients.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that changes may be made in the embodiments and/or equivalents thereof without departing from the spirit and scope of the invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (4)
1. The gardenia early granule formula is characterized in that the raw medicine quantity of the formula is as follows: 3-9g of radix bupleuri, 7-13g of cape jasmine, 7-13g of scutellaria baicalensis, 3-9g of moutan bark, 7-13g of radix curcumae, 7-13g of rhizoma cyperi, 7-13g of snakegourd fruit, 7-13g of selfheal, 7-13g of thunberg fritillary bulb, 7-13g of lychee seed, 7-13g of bighead atractylodes rhizome, 3-9g of dried orange peel, 3-9g of rhizoma pinelliae preparata and 7-13g of white paeony root.
2. The gardenia early granule formulation according to claim 1, wherein the raw drug amount of the formulation is: 6g of radix bupleuri, 10g of cape jasmine, 10g of radix scutellariae, 6g of moutan bark, 10g of radix curcumae, 10g of rhizoma cyperi, 10g of trichosanthes kirilowii maxim, 10g of selfheal, 10g of thunberg fritillary bulb, 10g of lychee seed, 10g of bighead atractylodes rhizome, 6g of dried orange peel, 6g of rhizoma pinelliae preparata and 10g of white paeony root.
3. The gardenia early granule formulation according to claim 1, wherein the raw drug amount of the formulation is: 3g of radix bupleuri, 7g of cape jasmine, 7g of radix scutellariae, 3g of moutan bark, 7g of radix curcumae, 7g of rhizoma cyperi, 7g of fructus trichosanthis, 7g of selfheal, 7g of thunberg fritillary bulb, 7g of lychee seed, 7g of rhizoma atractylodis macrocephalae, 3g of dried orange peel, 3g of rhizoma pinelliae preparata and 7g of radix paeoniae alba.
4. The gardenia early granule formulation according to claim 1, wherein the raw drug amount of the formulation is: 9g of radix bupleuri, 13g of cape jasmine, 13g of radix scutellariae, 9g of moutan bark, 13g of radix curcumae, 13g of rhizoma cyperi, 13g of trichosanthes kirilowii maxim, 13g of selfheal, 13g of thunberg fritillary bulb, 13g of lychee seed, 13g of rhizoma atractylodis macrocephalae, 9g of dried orange peel, 9g of rhizoma pinelliae preparata and 13g of radix paeoniae alba.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110475408.4A CN113509535A (en) | 2021-04-29 | 2021-04-29 | Cape jasmine-honeysuckle flower-all-grass-all particle formula |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110475408.4A CN113509535A (en) | 2021-04-29 | 2021-04-29 | Cape jasmine-honeysuckle flower-all-grass-all particle formula |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113509535A true CN113509535A (en) | 2021-10-19 |
Family
ID=78063545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110475408.4A Pending CN113509535A (en) | 2021-04-29 | 2021-04-29 | Cape jasmine-honeysuckle flower-all-grass-all particle formula |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113509535A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115120690A (en) * | 2022-06-08 | 2022-09-30 | 宁波市第一医院 | Traditional Chinese medicine composition for treating sexual precocity and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101176781A (en) * | 2006-11-06 | 2008-05-14 | 陈永辉 | Chinese medicine for curing children sexual precosity |
-
2021
- 2021-04-29 CN CN202110475408.4A patent/CN113509535A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101176781A (en) * | 2006-11-06 | 2008-05-14 | 陈永辉 | Chinese medicine for curing children sexual precosity |
Non-Patent Citations (1)
Title |
---|
杨丽珍,等: "栀早颗粒治疗女童肝郁痰结型特发性性早熟30例临床观察", 《中医药信息》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115120690A (en) * | 2022-06-08 | 2022-09-30 | 宁波市第一医院 | Traditional Chinese medicine composition for treating sexual precocity and application thereof |
CN115120690B (en) * | 2022-06-08 | 2023-06-27 | 宁波市第一医院 | Traditional Chinese medicine composition for treating precocious puberty and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104547579A (en) | Medicine composition for treating hyperprolactinemia infertility and application of medicine composition | |
CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
CN109528980B (en) | Traditional Chinese medicine composition for treating ovarian reserve function decline disease and pharmaceutical application thereof | |
CN104922613A (en) | Medicine composite for treating sterility and preparation method thereof | |
CN113509535A (en) | Cape jasmine-honeysuckle flower-all-grass-all particle formula | |
CN104958448A (en) | Medicine for treating puerperal infection | |
CN114177256B (en) | Traditional Chinese medicine composition for treating ovarian reserve hypofunction and application thereof | |
CN101411801A (en) | Method for preparing Chinese medicinal composition for anti-abortion and formulation thereof | |
CN110237161B (en) | Medicine for treating menopausal syndrome and preparation method and application thereof | |
CN101129864A (en) | Traditional Chinese medicine for treating tonicity headache | |
CN108403919B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
CN113599475A (en) | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
CN112773865A (en) | Composition with kidney tonifying and menstruation regulating functions and application | |
CN106729283A (en) | A kind of Chinese medicine composition for progestogenic of being promoted the sexual maturity for domestic animal and preparation method thereof | |
CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
WO2022057157A1 (en) | Traditional chinese medicine composition for treating precocious puberty in children, and preparation method therefor and use thereof | |
CN105641445A (en) | Medicine composition for treating pubertal polycystic ovary syndrome and preparation method | |
CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
CN111481614A (en) | Application of Wubi yam pills in preparation of medicine for treating perimenopausal syndrome | |
CN103520354A (en) | Traditional Chinese medicine for treatment of blood-insufficiency type mammary gland hyperplasia and preparation method thereof | |
CN110876781B (en) | Traditional Chinese medicine composition for treating kidney-yin deficiency type intermenstrual bleeding and night sweat and application thereof | |
CN106620066A (en) | Traditional Chinese medicine composition for promoting estrus and pregnancy of animals and preparation method thereof | |
CN105412768A (en) | Medicine composition for treating infertility and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211019 |
|
RJ01 | Rejection of invention patent application after publication |